Allogene’s 2026 inflection point could determine whether off-the-shelf CAR T becomes a scalable, outpatient, frontline and autoimmune treatment platform—or remains an unproven biotech promise.
Overview
Allogene is entering a defining clinical period after positive ALPHA3 interim data showed cema-cel cleared MRD in 58.3% of treated frontline LBCL patients versus 16.7% under observation, with no CRS, ICANS, GvHD, treatment-related SAEs, or hospitalizations. The company is attempting to prove off-the-shelf CAR T can be safe, outpatient, scalable, and earlier-line. With ALLO-329 autoimmune proof-of-concept data expected in 2026 and cash runway into Q1 2029, the investment case now hinges on translating molecular clearance into durable EFS benefit.